Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Alpha Tau’s Alpha DaRT Gains US Tolmar Deal; REGAIN GBM Data Key Catalyst

Aug 10, 2026, 4:04 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Major trial readouts and a large U.S. commercialization deal reduce execution risk and de-risk value, likely triggering re-rating as milestones approach and data readouts accumulate.

AI summary

What happened, with direct paths to the underlying reporting

Alpha Tau reported groundbreaking REGAIN results for recurrent GBM: 100% local disease control and 67% complete responses, with FDA clearance to expand enrollment. The Tolmar collaboration creates a U.S. commercialization path for Alpha DaRT, including equity and facility funding, underpinning a multi-indication growth runway. Additional pancreatic cancer data and ReSTART enrollment completion reinforce near-term catalysts and potential upside.

REGAIN GBM: 100% local control; 67% complete responses.
FDA clears enrollment expansion and adds two U.S. sites.
Tolmar deal accelerates U.S. Alpha DaRT commercialization.
Pancreatic cancer data show strong local control and encouraging OS.
ReSTART enrollment completed; 88 patients in U.S. pivotal cSCC program.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Alpha Tau’s Alpha DaRT Gains US Tolmar Deal; REGAIN GBM Data Key Catalyst

DRTS Shows Promising Results Amidst Strong Stock Momentum